TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
SciSparc Ltd. ( (SPRC) ) has provided an update.
On November 26, 2025, SciSparc Ltd. announced a binding term sheet to acquire a comprehensive portfolio of patents, trademarks, and intellectual property rights related to innovative endoscopic systems and medical cameras, including the MUSE™ system, from Xylo Technologies Ltd. This acquisition aims to replicate Xylo’s successful commercialization model in Greater China across high-growth markets like North America, Europe, and Latin America. The transaction, subject to definitive agreements and customary closing conditions, involves issuing Xylo 19.99% of SciSparc’s share capital or pre-funded warrants. This strategic move is expected to enhance SciSparc’s market positioning and unlock substantial revenue streams in the growing global GERD device market, projected to reach $3.03 billion by 2030.
More about SciSparc Ltd.
SciSparc Ltd., through its majority-owned subsidiary NeuroThera Labs Inc., is engaged in clinical-stage pharmaceutical developments focusing on cannabinoid pharmaceuticals. The company is involved in drug development programs targeting conditions such as Tourette syndrome, Alzheimer’s disease, and autism spectrum disorder. Additionally, SciSparc has a controlling interest in a subsidiary that sells hemp seed oil-based products on Amazon.
Average Trading Volume: 4,690,838
Technical Sentiment Signal: Sell
Current Market Cap: $3.96M
See more data about SPRC stock on TipRanks’ Stock Analysis page.